May. 8 at 2:55 PM
$BNTX
post from german board, where facts matter (no fake culture @dog)
Bristol Myers Squibb will pay out a guaranteed two billion this year, plus additional revenue from the coronavirus pandemic. This means the company is likely to end up at roughly break-even.
In addition, there is a possibility that approximately one billion will be received from Poland, Romania, and Hungary for payments that are still outstanding. I have already factored in Pfizer’s 50 percent share, leaving a net amount of just under one billion.
In addition, there is still
$7.6 billion in milestone payments pending from Bristol Myers Squibb. I expect these payments to materialize. Especially when a company launches a share buyback program, it is often a strong indication that the inflow of these funds is expected in the foreseeable future.
They have 20 billion $ cash at hand (made by covid injections)
What you are waiting for this company sells below cash literally. 1 buck for 1.20 Bucks.
